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to	 the	 recovery	of	 a	more	 concentrated	 sample	of	material,	with	 a	 significantly	higher	 level	of	
total	 and	 influenza	 H1-specific	 IgA.	 However,	 an	 equivalent	 percentage	 of	 specific	 IgA	 was	
observed	with	all	sampling	methods	when	normalised	to	the	total	IgA.	Responses	measured	using	
a	 recently	 developed	 antibody	 microarray	 platform,	 which	 allows	 evaluation	 of	 binding	 to	
multiple	 influenza	 strains	 simultaneously	with	 small	 sample	 volumes,	were	 compared	 to	ELISA.	
There	 was	 a	 good	 correlation	 between	 ELISA	 and	microarray	 values.	Material	 recovered	 from	









(LAIV),	 antibody-mediated	 protection	 at	 mucosal	 surfaces	 is	 thought	 to	 play	 a	 key	 role	 in	
preventing	influenza	infections1.	 In	particular	 IgA	at	mucosal	surfaces	has	been	shown	to	play	a	
role	 in	 reducing	 viral	 shedding2.	 To	 support	 the	 assessment	 of	 mucosal	 influenza	 vaccines	 in	
future	 clinical	 trials	 and	 studies	 of	 naturally-acquired	 mucosal	 immunity,	 standardized	 sample	
collection	 methods	 from	 nasal	 mucosal	 lining	 fluid	 (MLF)	 are	 required	 that	 acceptable	 to	
participants	 (especially	 young	 children)	 and	 collect	 consistent	MLF	 volumes.	 Furthermore,	 the	
volume	 collected	 and	 concentration	 of	 influenza-specific	 antibodies	 should	 be	 sufficient	 to	
measure	mucosal	responses	to	all	influenza	strains	included	in	the	vaccine.	These	aspects	are	also	
dependent	 on	 the	 requirements,	 performance	 and	 sensitivity	 of	 the	 IgA	 assay	 used,	 which	
traditionally	has	been	based	on	ELISA	techniques.		
	
We	present	 the	 results	of	a	pilot	 study	assessing	different	methods	 for	 collecting	nasal	MLF	 to	
detect	both	total	and	influenza-specific	IgA:	(i)	nasal	wash,	the	method	traditionally	used	for	this	
purpose	 but	 challenging	 in	 young	 children	 and	 subject	 to	 erratic	 sample	 recovery	 (ii)	 flocked	
swabs	and	(iii)	synthetic	absorptive	matrix	(SAM)	strips.	We	also	compare	a	highly	sensitive	ELISA	











due	 to	 prior	 studies	 showing	 a	 mucosal	 IgA	 response	 to	 LAIV	 in	 both	 children	 and	 adults	 at	
approximately	1	month	after	vaccination6,7.	Subjects	were	administered	tetravalent	LAIV	into	the	
nasal	 cavity	 (0.1ml	 per	 nostril).	 This	 vaccine	 contained	 the	 haemagglutinin	 (HA)	 and	
neuraminidase	 (NA)	 from	 a	A/California/7/2009	 (H1N1)	 pdm09-like	 strain	 (A/Bolivia/559/2013)	







already	 established	 protocols	 using	 these	 methods.	 Nasal	 swabs	 were	 inserted	 into	 the	 nasal	
cavity	 and	 repeatedly	 rotated	 360˚	 for	 approximately	 5	 seconds.	 Secretions	 were	 eluted	 by	
centrifugation	at	4˚C	through	a	Costar®	spin-X®	tube	(0.22µm	pore	size,	Sigma,	UK)	pre-incubated	
with	 300µl	 of	 extraction	 buffer	 (EB:	 phosphate	 buffered	 saline	 (PBS)	 containing	 0.02%	 sodium	
azide	 and	 0.25M	NaCl).	 Repeat	 centrifugation	with	 a	 further	 300µl	 of	 EB	was	 performed.	One	
swab	from	each	nostril	was	obtained	and	eluted	material	pooled.	A	single	SAM	strip	was	inserted	











anti-Human	 lambda	 capture	 antibodies	 (Southern	 Biotech,	UK)	 at	 4˚C	 for	 16	 –	 18	 hours.	 After	
washing	in	PBS-T	(PBS	with	0.05%	Tween®20	(Sigma,	UK)),	plates	were	blocked	with	assay	buffer	
(AB;	 1:1	 Casein	 blocking	 buffer	 (Thermofisher	 scientific,	 UK)	 and	 PBS)	 for	 1	 hour	 at	 37˚C.	MLF	
samples	were	diluted	1:1,000,	1:5,000	and	1:25,000	and	incubated	for	1	hour	at	37˚C	in	triplicate,	
along	with	 a	 serial	 dilution	 of	 human	 IgA	 (from	 colostrum,	 Sigma,	 UK)	 to	 generate	 a	 standard	
curve	(range	200ng/ml	to	0.195ng/ml).	After	washing	with	PBS-T,	 IgA	antibodies	were	detected	
using	 biotin-labelled	 Goat	 anti-human	 IgA	 (Insight	 Biotechnology	 Ltd,	 UK)	 followed	 by	
streptavidin-poly-HRP40	 (2BScientific,	 UK)	 and	 signal	 developed	 using	 SureBlue	 TMB	Microwell	
Peroxidase	 Substrate	 and	 TMB	 Stop	 solution	 (both	 from	 Insight	 Biotechnology	 Ltd,	 UK).	 After	
development,	 plates	 were	 read	 at	 450nm	 using	 a	 VersaMax	 plate	 reader.	 Generation	 of	 the	
standard	 curve	 and	 total	 IgA	quantification	 in	 samples	was	performed	 following	 subtraction	of	
background	optical	density	 (OD)	values.	 	A	mean	estimated	 IgA	value	of	dilutions	 falling	within	
the	 linear	 portion	 of	 the	 standard	 curve	 were	 included	 in	 final	 calculations.	 Some	 SAM	 strip-












sera4	 was	 adapted	 to	 detect	 anti-influenza	 IgA	 in	 MLF	 samples.	 Briefly,	 nitrocellulose	 coated	
slides	 (ONCYTE®	 AVID,	 Grace	 Bio-Labs,	 USA)	 were	 spotted	 in	 duplicate	 with	 recombinant	 HA1	
protein	 from	 both	 A/California/6/2009	 (H1N1pdm09)	 and	 A/Brisbane/10/2007	 (H3N2).	 These	
were	used	 to	detect	anti-influenza	 IgA	 in	40	operator-blinded	samples	 (consisting	of	day	0	and	
day	 28	 swab	 and	 strip-eluted	 material	 from	 10	 subjects).	 Slides	 were	 treated	 with	 Blocker™	
BLOTTO	blocking	buffer	(Thermo	Fisher	Scientific,	USA)	for	1	hour	at	37˚C.	After	washing,	samples	
were	 diluted	 1:3	 and	 transferred	 to	 the	 arrays.	 Following	 incubation	 for	 1	 hour	 at	 37˚C,	 slides	
were	washed	 and	 incubated	with	 goat	 anti-human	 IgA	 conjugated	with	Dylight649-fluorescent	
dye	(Jackson	ImmunoResearch,	USA)	for	a	further	1	hour	at	37˚C.	After	washing,	slides	were	dried	
and	signals	quantified	by	a	PowerScanner™	microarray	scanner	(Tecan	Trading	AG,	Switzerland).	

















Based	 on	 a	 previous	 study	 comparing	 allergen-specific	 IgA	 detection	 in	 SAM	 strips	 and	 nasal	
washes13,	we	 calculated	 that	 5	participants	would	be	 sufficient	 to	detect	 a	 2-fold	difference	 in	
anti-influenza	 IgA	 levels	 at	 day	 28	 post-LAIV	 between	 these	 two	methods	 (power	 90%,	 alpha	
0.01).	To	account	for	a	proportion	of	subjects	without	detectable	IgA	and	potential	dropouts,	we	
aimed	 to	 recruit	 10	 –	 15	 participants.	 All	 statistical	 analyses	 were	 performed	 using	 GraphPad	
Prism	 version	 5.0	 for	Macintosh.	 Differences	 in	 IgA	 levels	 among	 the	 three	 sampling	methods	
were	 investigated	 using	 the	 Friedman’s	 test.	 The	 non-parametric	 pairwise	multiple	
comparisons	procedure,	 Dunn’s	 test,	 was	 used	 for	 post-hoc	 comparison	 whenever	 the	 null	











(32.3,	 137.0)	 and	 55.9µg/ml	 (24.5,	 90.4)	 respectively.	 H1pdm09	 HA-specific	 IgA	 concentration	
was	approximately	5-fold	higher	 in	SAM	strip-collected	material:	median	118.1ng/ml	 (IQR	40.9,	













between	 nasal	 swabs	 and	 SAM	 strips	 than	 raw	 values	 at	 both	 day	 0	 and	 day	 28	 (Fig	 2).	 	 The	
percentage	H1pdm09	HA-specific	 IgA	 in	nasal	washes	was,	however,	significantly	higher	than	 in	
flocked	swabs	at	day	28.	This	may	reflect	the	trend	towards	a	greater	yield	of	total	IgA	in	swabs	
compared	 to	 washes	 (Fig	 1a).	 A	 good	 correlation	 is	 seen	 between	 percentage	 H1pdm09	 HA-
specific/total	 IgA	 values	 between	methods	 in	 each	 subject	 (Fig	 3),	 with	 the	 most	 comparable	






to	measure	antibodies	to	all	antigens	 included	 in	seasonal	 influenza	vaccines.	HA	microarray4	 is	
able	to	reliably	detect	anti-influenza	IgG	in	very	small	quantities	of	serum	(10µl),	so	we	tested	the	
ability	of	this	assay	to	detect	anti-influenza	IgA	in	MLF.	Due	to	sample	volume	availability,	H3	HA-
specific	 IgA	ELISAs	were	only	performed	on	 flocked	swab	 (and	not	SAM	strip)	material.	A	good	
correlation	 was	 seen	 between	 both	 H1pdm09	 HA	 and	 H3	 HA	 influenza-specific	 IgA	 levels	
(fluorescence	units)	in	the	HA	microarray	and	IgA	quantified	by	ELISA	in	ng/ml	(Fig	4).	This	was	in	





(in	 each	 case	 normalized	 by	 the	 total	 IgA	 quantity).	 A	 ≥2-fold	 increase	 was	 considered	 a	
significant	response	as	defined	in	a	previous	LAIV	study6.	This	was	undertaken	for	swab	samples	
in	 the	 10	 subjects	 for	 whom	 comparable	 H1pdm09	 and	 H3-specific	 data	 were	 available	







To	 evaluate	 a	 more	 functional	 readout	 of	 anti-influenza	 activity	 in	 MLF,	 available	 SAM	 strip-
collected	material	(as	those	with	the	greatest	antibody	yield)	were	tested	in	a	standard	influenza	
microneutralization	(MN)	assay.	While	11/25	of	samples	tested	showed	detectable	titres	against	








Reliable,	 high-yield,	 participant-acceptable	 methods	 to	 assess	 mucosal	 anti-influenza	 humoral	
activity	are	vital	 in	studies	of	both	natural	 infection	and	vaccine-induced	immunity.	We	provide	
(to	our	knowledge	for	the	first	time)	a	direct	comparison	of	nasal	washes	with	flocked	swabs	and	
SAM	 strips	 to	 collect	 MLF	 and	 measure	 influenza-specific	 IgA	 responses,	 with	 the	 latter	 two	
representing	 techniques	 with	 greater	 convenience	 for	 both	 the	 investigator	 and	 study	
participant.	
	
We	demonstrate	 that	 the	yield	of	 total	 and	 influenza-specific	 IgA	 is	 significantly	higher	 in	 SAM	
strips	 compared	 to	 flocked	 swabs	 or	 nasal	washes.	 This	 is	 in	 keeping	with	 previous	 reports	 of	
greater	cytokine13,14	and	allergen-specific	antibody13	recovery	using	SAM	strips,	but	in	contrast	to	
a	 recent	 study	 showing	 SAM	 strips	 had	 lower	 HIV-1	 antibody	 recovery	 from	 nasal	 turbinates	
compared	to	flocked	swabs8.	The	reasons	for	this	difference	are	not	clear,	but	could	include	how	
long	 SAM	 strips	 remain	 in	 contact	 with	 the	 nasal	 mucosa,	 environmental	 variation	 affecting	
mucosal	moistness	and	pre-incubation	of	Costar®	spin-X®	tubes	with	elution	buffer,	all	of	which	
may	 affect	 antibody	 yield.	 Despite	 the	 known	 variability	 of	 nasal	 IgA	 secretion	 (including	
diurnally15),	 we	 also	 observed	 a	 significant	 correlation	 between	 day	 0	 and	 day	 28	 total	 IgA	
recovery	 for	 each	 subject	 in	 flocked	 swab	 and	 SAM	 strip	 samples,	 but	 not	 nasal	 washes.	 This	
supports	 the	 hypothesis	 that	 swabs	 and	 SAM	 strips	 are	 more	 consistent	 sample	 collection	
methods	compared	to	washes.		
	
Given	 the	 small	 volumes	 of	 nasal	 MLF	 obtainable,	 sensitive	 assays	 are	 required	 to	 measure	
influenza-specific	 humoral	 immunity	 in	 these	 samples.	 One	 potential	 drawback	 of	 ELISA	 is	 the	
high	volume	of	sample	required,	especially	 if	 low	antibody	 levels	necessitate	 running	undiluted	
material	and	IgA	specific	to	several	antigens	are	measured.	We	therefore	evaluated	the	ability	of	
a	 protein	 microarray4	 to	 detect	 nasal	 influenza-specific	 IgA	 and	 demonstrated	 an	 excellent	
correlation	with	 ELISA	 data.	 Furthermore,	 this	 assay	was	 able	 to	 quantify	 IgA	 (in	 fluorescence	
units)	 in	samples	with	a	wide	range	of	ELISA-quantified	 IgA	values	 (2.7ng/ml	–	1437ng/ml)	at	a	
single	sample	dilution	 (1:3),	 thus	reducing	the	potential	errors	 introduced	by	requiring	multiple	
different	dilutions	across	 samples	 to	 fall	within	a	 range	detectable	by	ELISA.	 This	methodology	




We	 also	 sought	 to	 measure	 functional	 responses	 in	 SAM	 strip	 samples	 by	 using	 a	 standard	
influenza	MN	assay.	Although	neutralizing	antibody	was	detected	in	44%	of	samples	tested,	titres	






make	 a	 more	 significant	 contribution	 to	 neutralization	 measured	 by	 the	 in	 vitro	 assay	 used.	
Interestingly,	the	correlation	between	MN	activity	and	H1pdm09	influenza-specific	IgA	detected	
in	 the	microarray	was	 greater.	Whether	microarray-detected	 IgA	 levels	 are	 a	 better	 surrogate	
marker	 of	 neutralizing	 activity	 in	 nasal	 MLF	 than	 ELISA-quantified	 values	 requires	 further	
investigation.	 There	 remains	 a	 need	 to	 combine	 a	 functional	 assay	 with	 a	 convenient	 MLF	
sampling	method.		
	
Finally,	 although	 the	main	 purpose	 of	 the	 study	 was	 to	 evaluate	 sampling	methods	 and	 anti-
influenza	 IgA	detection	 assays,	we	 assessed	 the	mucosal	 IgA	 response	 to	 the	H1N1pdm09	and	
H3N2	components	in	tetravalent	LAIV	in	the	limited	sample	of	adults	in	the	study.	Using	a	≥2-fold	
increase	 from	 baseline	 post-LAIV	 as	 a	 significant	 response6,	 none	 of	 ten	 subjects	 showed	 a	
H1N1pdm09-specific	 response,	 with	 one	 subject	 showing	 a	 H3N2-specific	 response	 in	 ELISA-
measured	 influenza-specific	 IgA	 data.	 This	 is	 consistent	 with	 previous	 reports	 of	 lower	 LAIV	
efficacy	in	adults	compared	to	children17	and	poor	antibody	responses	to	H1N1pdm09	compared	
to	 H3N2	 or	 influenza	 B	 components	 in	 LAIV	 even	 in	 children18,19.	 Interestingly,	 when	 we	
considered	the	influenza-specific	IgA	data	generated	by	HA	microarray,	three	subjects	showed	a	
significant	response	to	H1	HA	and	three	subjects	to	H3	HA	(2	subjects	showed	a	≥2-fold	increase	
to	both	H1pdm09	and	H3	HA).	 It	 is	difficult	 to	 conclude	 from	 these	data	whether	 the	ELISA	or	












H1-specific	 IgA	 (b)	 in	 nasal	 swabs,	 SAM	 strips	 and	 nasal	 washes	 quantified	 by	 indirect	 ELISA	
(Friedman	test	with	Dunn’s	posttest	for	multiple	comparisons)	at	day	0	and	day	28.	Comparisons	


































































p < 0.01 p < 0.001
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NS
NS p < 0.05
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rs = 0.6868, p < 0.01
SAM strip



























Figure	2.	The	proportion	of	 specific	 IgA	as	a	percentage	of	 total	 IgA	 is	 constant	 regardless	of	
sampling	method.	Comparison	 of	 total	H1-specific	 IgA	 yield	 from	nasal	 swabs,	 SAM	 strips	 and	
nasal	washes,	expressed	as	a	%	of	total	IgA	detected	in	the	same	sample	at	day	0	and	28.	Values	
were	 quantified	 by	 indirect	 ELISA	 and	 comparisons	made	using	 the	 Friedman	 test	with	Dunn’s	




































































Figure	3.	Correlation	between	 the	H1-specific	 IgA	yield	 (expressed	as	a	%	of	 total	 IgA)	between	
















Nasal swab vs nasal wash (day 0)




















rs = 0.8803, p < 0.0001
Nasal swab vs nasal wash (day 28)



















Nasal swab (%H1/Total IgA)
rs = 0.6226, p = 0.02
SAM strip vs nasal wash (day 0)




















rs = 0.8077, p < 0.001
SAM strip vs nasal wash (day 28)



















SAM strip (%H1/Total IgA)
rs = 0.6924, p < 0.01
SAM strip vs nasal swab (day 0)






















rs = 0.8391, p < 0.001
SAM strip vs nasal swab (day 28)
























Figure	 4.	 Influenza	 specific	 IgA	 levels	 detected	 are	 similar	 when	 measured	 by	 ELISA	 or	
microarray.	Correlations	 between	 H1-specific	 (a)	 and	 H3-specific	 (b)	 IgA	 in	mucosal	 lining	 fluid	
samples	detected	by	protein	microarray	and	ELISA.	H1-specific	comparisons	include	pre	and	post-










































































Spearman's rho = 0.8921
p < 0.0001
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Reciprocal of sample dilution at which 
50% virus inhibition observed in MN assay
rs = 0.4742, p = 0.01







Reciprocal of sample dilution at which 










































H1	 H3	 H1	 H3	 		 Day	0	 Day	28	
1	 1.25	 1.26	 1.81	 1.63	 		 89	 72	
2	 1.80	 1.21	 3.94	 ††	 		 9	 35	
3	 1.99	 1.72	 0.95	 0.80	 		 160	 74	
4	 1.41	 1.26	 4.02	 2.49	 		 39	 59	
5	 1.10	 1.17	 1.76	 1.17	 		 217	 98	
6	 1.25	 1.58	 2.20	 2.07	 		 128	 182	
7	 0.65	 0.84	 1.36	 1.04	 		 148	 73	
8	 0.92	 12.93	 1.02	 8.59	 		 107	 133	
9	 1.16	 †	 0.44	 0.28	 		 27	 83	
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